Condensed Consolidated Statements of Mezzanine Equity and Changes in Stockholders' Equity (unaudited) - USD ($)	Convertible preferred stock Series G Convertible Preferred Stock	Convertible preferred stock Series B Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at the beginning (in shares) at Dec. 31, 2022		550	49,750
Balance at the beginning at Dec. 31, 2022			$ 5	$ 171,275,836	$ (168,533,689)	$ 2,742,152
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs			$ 1	3,769,910		3,769,911
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs (in shares)			6,400
Exercise of pre-funded warrants into common stock			$ 2	299		301
Exercise of pre-funded warrants into common stock (in shares)			21,473
Deemed dividend of Series B preferred stock				(87,431)		$ (87,431)
Conversion of Series B preferred shares into common stock (in shares)		(4)	4
Stock cancelled during period, shares, acquisitions (in shares)						148
Effect of cancelled shares from the reverse stock split (in shares)			(148)
Stock-based compensation				358,316		$ 358,316
Net income (loss)					(4,070,653)	(4,070,653)
Balance at the end (in shares) at Mar. 31, 2023		546	77,479
Balance at the end at Mar. 31, 2023			$ 8	175,316,930	(172,604,342)	2,712,596
Balance at the beginning (in shares) at Dec. 31, 2023		515	1,560,998
Balance at the beginning at Dec. 31, 2023			$ 156	187,931,445	(184,328,672)	3,602,929
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs			$ 17	3,604,919		3,604,936
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs (in shares)			173,100
Issuance of stock upon acquisition of IMGX	$ 57,790,474		$ 4	2,300,496		2,300,500
Issuance of stock upon acquisition of IMGX (in shares)	11,777		36,830
Issuance of stock to financial advisors	$ 3,890,626		$ 2	120,646		120,648
Issuance of stock to financial advisors (in shares)	596		18,475
Exercise of pre-funded warrants into common stock			$ 9			9
Exercise of pre-funded warrants into common stock (in shares)			83,525
Deemed dividend of Series B preferred stock				(66,144)		(66,144)
Conversion of Series B preferred shares into common stock (in shares)		(10)	9
Common stock issued to consultants			$ 10	780,990		781,000
Common stock issued to consultants (in shares)			100,000
Issuance of common stock from RSU vest			$ 5	(5)
Issuance of common stock from RSU vest (in shares)			52,271
Stock-based compensation				271,360		271,360
Net income (loss)					5,567,606	5,567,606
Balance at the end (in shares) at Mar. 31, 2024	12,373	505	2,025,208
Balance at the end at Mar. 31, 2024	$ 61,681,100		$ 203	$ 194,943,707	$ (178,761,066)	$ 16,182,844